The Korea Herald · All News

Samsung Bioepis, G2GBio partner on long-acting obesity drug development

· By Jeon Ji-woo
Story summary

Samsung Bioepis and Epis NexLab, subsidiaries of Samsung Epis Holdings, have signed a joint research and licensing agreement with Korean biotech G2GBio to develop long-acting obesity treatments, the companies said Monday.

Read at The Korea Herald

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.

Your local edition.

Choose a timezone for story timestamps and date filters.